Application of Aidi Injection (艾迪注射液) in the Bronchial Artery Infused Neo-Adjuvant Chemotherapy for stage ⅢA Non-small Cell Lung Cancer before surgical Operation

Objective： To study the effect of Aidi Injection （艾迪注射液,ADI） applied in the bronchial artery infused （BAI） neo-adjuvant chemotherapy for stage ⅢA non-small cell lung cancer （NSCLC） before surgical operation.Methods： The 60 patients with NSCLC stage ⅢA underwent two courses BAI chemotherapy before tumor incision were assigned to two groups,the treatment and the control groups,using a random number table,30 in each group.ADI （100 mL） was given to the patients in the treatment group by adding into 500 mL of 5% glucose injection for intravenous dripping once daily,starting from 3 days before each course of chemotherapy,and it lasted for 14 successive days,so a total of 28 days of administration was completed.The therapeutic effectiveness and the adverse reaction that occurred were observed,and the levels of T-lymphocyte subsets,natural killer cell activity,and interleukin-2 in peripheral blood were measured before and after the treatment.Results： The effective rate in the treatment group was higher than that in the control group （70.0% vs.56.7%,P〈0.05）.Moreover,as compared with the control group,the adverse reaction that occurred in the treatment group was less and mild,especially in terms of bone marrow suppression and liver function damage （P〈0.05）.Cellular immune function was suppressed in NSCLC patients,but after treatment,it ameliorated significantly in the treatment group,showing significant difference as compared with that in the control group （P〈0.05）.Conclusion： ADI was an ideal auxiliary drug for the patients in stage ⅢA NSCLC received BAI neo-chemotherapy before surgical operation;it could enhance the effectiveness of chemotherapy,ameliorate the adverse reaction and elevate patients＇ cellular immune function;therefore,it is worthy for spreading in clinical practice.

Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients

To evaluate the efficacy of adjuvantchemotherapy after radical surgery for non-small-celllung cancer (NSCLC). Methods Seventy patients with NSCLC (stages Ⅰ -Ⅲ ) undergoing radical surgery were randomized intotwo groups. Group 1 (n = 35): combination group,which received adjuvant chemotherapy withcyclophosphamide 300 mg/m 2, vincristine 1. 4 mg/m 2,adriamycin 50 mg/m 2, and lomustine 50 mg/m 2 on day1, and cisplatin 20 mg/m 2 on days 1-5. Thetreatment was repeated every 4-6 weeks for 4 cycles,followed by oral administration of ftorafur (FT-207) 600-900 mg/d for 1 year. Group 2 (n = 35): surgerygroup, which received surgical treatment only. Results The overall 5-year survival rate was 48.6%in the combination group versus 31 .4% in the surgerygroup, and difference between the two groups was notStatistically significant (x 2 = 3.09, P > 0.05). The year survival rate for patients with stage Ⅲ diseasewas 44% and 20.8% in the combination and surgerygroups, respectively, showing a statistically significantdifference (x 2 = 5.28, P < 0.025). The 5-yearsurvival rates of patients in stages Ⅰ -Ⅱ in the twogroups were 60.0% and 54.5%, respectively, andwere not significantly different (x 2 = 0. 03, P > 0. 75). Conclusion Postoperative adjuvant chemotherapy provides statistically significant improvement in the 5 year survival rate only in patients with stage ⅢNSCLC.

Shenyi Capsule(参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer:A Systematic Review of Overlapping Meta-Analyses

Objective：To assist decision-makers interpret and choose among conflicting meta-analyses,as well as to offer treatment recommendations based on current best evidence by performing a systematic review of overlapping meta-analyses regarding Shenyi Capsule（参一胶囊,SC） plus chemotherapy versus chemotherapy of non-small cell lung cancer（NSCLC）.Methods：A literature search was conducted to select systematic reviews comparing SC plus chemotherapy with chemotherapy for NSCLC.Meta-analyses only composed of randomized controlled trials（RCTs） met the inclusion criteria.Two authors individually estimated the quality of meta-analysis and extracted data.The Jadad decision algorithm was applied to guarantee which meta-analysis provided the best original evidence.Results：A total of 5 meta-analyses were included.All the studies composed of RCTs or quasi-RCTs and were regarded as level-Ⅱ evidence.The scores of the Assessment of Multiple Systematic Reviews ranged from 3 to 6（median 4）.A high-quality meta-analysis with more RCTs was chosen,which suggested that SC plus chemotherapy could increase incidence of short-term efficacy,improve the quality of life and survival rate in comparison to chemotherapy.However,there was no statistically significant difference between SC plus chemotherapy and chemotherapy regarding chemotherapy-induced side effect,such as liver and kidney function obstacle,leukopenia,hemoglobin decrement and gastrointestinal adverse reaction.Conclusions：Based on the best available evidence,treatment effect of SC plus chemotherapy was better than chemotherapy and did not increase side effects.Therefore,SC plus chemotherapy may be superior to chemotherapy for treating NSCLC.However,due to some limitations,SC plus chemotherapy should be cautiously considered,and further high-quality meta-analyses are needed.

Longer Overall Survival in A Patient with Advanced Non-small Cell Lung Cancer Treated with Chinese Medicine and Chemotherapy

Non-small cell lung cancer （NSCLC） is the leading cause of cancer death in the industrialized world. Despite significant progress in early stage of the disease, the overall survival rates for advanced disease remain low. Herein we present a case of NSCLC who was treated with Chinese medicine and chemotherapy with a longer overall survival.

ADVANCE NON SMALL CELL LUNG CANCER ACCEPTING CHEMOTHERAPY COMBINED WITH SHENMAI INJECTION

The aim of the study was to observe the changes of vascular endothelial growth factor(VEGF)and the efficacy of patients with advanced non-small-cell lung cancer(NSCLC)after the treatment of chemotherapy with Shenmai Injection.This study is a randomized controlled,prospective,single blind trial.63 eligible patients with NSCLC were